Stockscreener 앱 받기
4.41
1.12%
-0.05
시간 외 거래:
4.24
-0.17
-3.85%
전일 마감가:
$4.46
열려 있는:
$4.43
하루 거래량:
301.21K
Relative Volume:
0.45
시가총액:
$1.01B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
8.0416
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-1.34%
1개월 성능:
+31.25%
6개월 성능:
+42.26%
1년 성능:
-11.62%
1일 변동 폭
$4.3499
$4.50
1주일 범위
$4.31
$4.82
52주 변동 폭
$2.37
$5.00
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
4.41 | 1.01B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac (NASDAQ:CVAC) Shares Purchased by Northern Trust Corp - Defense World
CureVac: Successful cash burn reduction - marketscreener.com
CureVac (NASDAQ:CVAC) Given “Market Outperform” Rating at JMP Securities - Defense World
D. E. Shaw & Co. Inc. Purchases New Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) Maintains Market Outperform Rating with Stable Price Target | CVAC Stock News - GuruFocus
CureVac stock maintains $10 target from JMP on GBM vaccine outlook - Investing.com UK
Millennium Management LLC Sells 771,136 Shares of CureVac (NASDAQ:CVAC) - Defense World
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business - simplywall.st
We Think CureVac's (NASDAQ:CVAC) Robust Earnings Are Conservative - Yahoo
CureVac First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
CureVac FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
BNP Paribas Financial Markets Takes $585,000 Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac Announces Annual General Meeting for June 2025 - TipRanks
Earnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
CureVac NV reports results for the quarter ended March 31Earnings Summary - TradingView
CureVac price target lowered to $2 from $2.50 at BofA - TipRanks
CureVac (CVAC): BofA Reduces Price Target Amidst Ongoing Challen - GuruFocus
CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring - TipRanks
CureVac Reports Q1 2025 Financial Results Amid Revenue Decline - TipRanks
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction - Benzinga
CVAC Reduces Operating Loss in Q1 2025 Amid Strong Pipeline Progress | CVAC Stock News - GuruFocus
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - ACCESS Newswire
CureVac Secures Major FDA Win for Cancer Drug While Patent Battle Against BioNTech Heats Up - Stock Titan
Curevac Q1 Revenue Eur 900 Thousand - marketscreener.com
CureVac granted favorable decision by European Patent Office vs. BioNTech - TipRanks
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE | CVAC Stock News - GuruFocus
CureVac Secures Critical Second Patent Win vs BioNTechJuly Court Showdown Set for mRNA Rights - Stock Titan
CureVac Secures Key Patent Victory in Litigation with BioNTech - TipRanks
Barclays PLC Has $118,000 Stake in CureVac (NASDAQ:CVAC) - Defense World
CureVac (CVAC) to Release Earnings on Thursday - Defense World
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):